Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cardiovascular Research

Background:

• Reperfusion therapy is crucial for acute stroke, but current treatments like recombinant tissue plasminogen activator have limitations.
• Hemorrhagic complications restrict thrombolytic use, necessitating targeted approaches for improved safety and efficacy.

Purpose of the Study:

• To develop fibrin-specific, perfluorocarbon nanoparticles for targeted delivery of streptokinase.
• To evaluate the in vitro effectiveness of these nanoparticles for targeted thrombolysis using acoustic microscopy.

Main Methods:

• In vitro human plasma clots were treated with streptokinase-loaded nanoparticles, control nanoparticles, or a combination.
• Quantitative acoustic microscopy was used to monitor clot morphology and backscatter changes over 1 hour.
• Clots were exposed to phosphate-buffered saline (PBS) with or without plasminogen and free streptokinase.

Main Results:

• Streptokinase-loaded nanoparticles significantly enhanced acoustic contrast, enabling volumetric clot estimation.
• Targeted nanoparticles rapidly induced fibrinolysis (<60 min) in the presence of plasminogen without adverse effects.
• Targeted streptokinase required significantly lower concentrations for effective clot lysis compared to free streptokinase.

Conclusions:

• A novel nanoparticle-based agent demonstrated specific and rapid in vitro fibrinolysis.
• This targeted thrombolytic approach holds potential for clinical application in acute ischemic stroke reperfusion therapy.